Acta Medica International

ORIGINAL ARTICLE
Year
: 2016  |  Volume : 3  |  Issue : 1  |  Page : 107--110

Fibromyalgia: Comorbidity or a psychosomatic symptom of depression leading to the abuse of opioids?


Francisco J Diaz1, Chantel Njiwaji2, LokMan Sung1,  
1 Assistant Professor, University of Michigan Pathology Department/Wayne County Medical Examiner, Detroit, MI, USA
2 Clinical Lecturer, University of Michigan Pathology Department/Wayne County Medical Examiner, Detroit, MI, USA

Correspondence Address:
Francisco J Diaz
Assistant Professor University of Michigan Pathology Department/Wayne County Medical Examiner, 1300 E Warren Ave, Detroit, MI. 48207
USA

Abstract

Introduction: We conducted a retrospective study at the Wayne County Medical Examiner Office, which examined decedents diagnosed with Fibromyalgia, a disorder of unknown etiology characterized by widespread chronic musculoskeletal pain, concomitant with fatigue, sleep disturbances, and psychological distress. Material & Methods: Over a seventeen year period a total of 54 cases from our database met this criterion. Other criteria in the study included cause and manner of death, post-mortem toxicology results, major autopsy findings, and medical history. Results: Our study revealed that the cause of death in approximately two-thirds of the cases was due to drug intoxication. The most frequent post-mortem toxicology finding was Opioids, such as Morphine, Hydrocodone, Oxycodone, Fentanyl, and Codeine. The most common manner of death was accident. Almost 90% of the decedents were Caucasian females, which contrasted with the demographic diversity of Wayne County, Michigan. Additional findings revealed that the average age was 47 years, and the average Body Mass Index (BMI) could be categorized as obese. Nearly 67% of the cases had a medical history of depression. Conclusion: Our findings suggest that Fibromyalgia might be a psychosomatic symptom of depression rather than comorbidity. Therefore, physicians should further inquire about, and consider treating, depression in patients with chronic musculoskeletal pain while completely avoiding the use of opioids, for opioids have a greater risk of being abused and resulting in death in such patients, as found in our study.



How to cite this article:
Diaz FJ, Njiwaji C, Sung L. Fibromyalgia: Comorbidity or a psychosomatic symptom of depression leading to the abuse of opioids?.Acta Med Int 2016;3:107-110


How to cite this URL:
Diaz FJ, Njiwaji C, Sung L. Fibromyalgia: Comorbidity or a psychosomatic symptom of depression leading to the abuse of opioids?. Acta Med Int [serial online] 2016 [cited 2019 Aug 17 ];3:107-110
Available from: http://www.actamedicainternational.com/text.asp?2016/3/1/107/209689


Full Text



[INLINE:1]

 Introduction



Fibromyalgia is defined as a disorder characterized by widespread chronic musculoskeletal pain concomitant with fatigue, sleep disturbances, and psychological distress. The etiology of the condition is unknown; however, the condition has substantial overlap with many rheumatologic disorders and other clinical disorders especially depression. The term “Fibromyalgia” was coined during the 1970s. In 1990, a diagnostic criteria was presented by the American College of Rheumatology (ACR). The criteria considered widespread chronic pain as occurring for three months on both sides of the body as well as above and below the waist. Pain in the axial skeleton had to be present and a certain amount of digital force had to be applied and elucidate pain to at least 11 out of 18 areas on the body. In 2010, the diagnostic criteria for fibromyalgia was changed and further modified in 2011. The criteria eliminated the tender point examination by the physician which was substituted with patient self-reporting scales. This revision, in our opinion, confounds and complicates the process of establishing a correct diagnosis.

Through the years at the Wayne County Medical Examiner Office we have observed that it is not unusual to find decedents with a past medical history of fibromyalgia. The purpose of this retrospective study was to ascertain the cause and manner of death in fibromyalgia cases, and further examine the relationship between fibromyalgia, depression, and the abuse of opioids. Our proposed question was: Given the high rate of depression and abuse of narcotics reported in fibromyalgia cases and the ongoing debate within the medical community regarding the validity of fibromyalgia as a stand-alone diagnosis, should fibromyalgia be considered a psychosomatic symptom of depression rather than a comorbidity of depression?

 Materials and Methods



From 1997 to 2014, the Wayne County Medical Examiner's Office in Detroit, Michigan, retrospectively identified from our database 54 cases which had a diagnosis of fibromyalgia. Additional criteria included the following: cause and manner of death, post-mortem toxicology results, major autopsy findings, and medical history.

 Results



Fifty four cases were identified with a verifiable medical history of fibromyalgia. The most common cause of death in these cases was drug-related [Table 1], 64.8 % died as a result of single or multiple drugs. The most common group of drugs was opiates: Morphine, codeine, oxycodone, hydrocodone and codeine. Benzodiazepines and antidepressants were also found [Figure 1].{Table 1}{Figure 1}

The remainder of the causes of death included the following: arteriosclerotic cardiovascular disease (ascvd) or other heart-related diseases, diabetes mellitus, pneumonia, pulmonary embolism a self-inflicted gunshot wound. The most common past medical history and co-morbidity included alcohol use and diabetes mellitus, respectively [Figure 2] and [Figure 3].{Figure 2}{Figure 3}

The most common manner of death was accident (67%) followed by natural (32%) and one suicide. [Figure 4] The average age was 47 and the average BMI was 32.6 and 90 % of the decedents were female and Caucasian. [Figure 5] and [Figure 6]. In the majority of the cases, 64.8% (35 out of 54 cases, decedent's had a psychiatric history of depression [Figure 7].{Figure 4}{Figure 5}{Figure 6}{Figure 7}

 Discussion



Fibromyalgia in clinical practice should be suspected in patients having multifocal pain not fully explained by injury or inflammation.[1] The prevalence rate is approximately 2-8% of the population depending on the diagnostic criteria used[2] The American College of Rheumatology criteria for diagnosis of fibromyalgia were published in 1990.[3]

Those criteria required that the patients had widespread pain as well as tenderness in 11 or more 18 possible “tenderness” points.[3] In 2011 a new set of criteria was introduced.[4] This new criteria does not take in to account the “tender points” and relies solely on symptoms including fatigue, sleep disturbances and mood disorders.

Patients diagnosed with fibromyalgia are more likely to have psychiatric disorders[1] including depression, anxiety and obsessive compulsive disorder. Those conclusions were corroborated by our cohort in which 35/54 patients had a clinical history of depression. Family members of patients diagnosed with fibromyalgia also may have a history of chronic pain disorder.[5] Certain type of infections has been associated with fibromyalgia such as Q fever, EBV and Lyme disease.[6] Other rheumatologic entities such as osteo- arthritis, rheumatoid arthritis and lupus usually co-exist with fibromyalgia.[7] Treatment of fibromyalgia include, among others, patient education,[8] cognitive behavioral therapy,[9] tricyclic compounds,[10] Serotonin reuptake inhibitors,[11] Nonsteroidal anti-inflammatory drugs[1] and opiates.[1] However there is increasing evidence that opiates are less effective for treating chronic pain and their risk- benefit profile is worse than other classes of analgesics.[1]

Vast majority of our cohorts were female and Caucasian in a population such as Wayne County, Michigan that has great ethnic diversity and contrasting with the assertion that fibromyalgia can develop at any age and the prevalence is similar in different countries, cultures and ethnic groups.[12]

Fibromyalgia is a relatively new diagnostic entity with a new set of diagnostic criteria and known psychological and nosocological associations. From the point of view of this study it represents another Variance in the general theme of drug abuse.

References

1Claw, D. Fibromyalgia A Clinical Review. Journal of the American Medical Association (JAMA).2014;Volume 311 (15):1547–1555.
2Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1):19–28.
3Wolfe F, Smythe HA, Yunus MB, et al; Report of the Multicenter Criteria Committee. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum. 1990;33(2):160–172.
4Wolfe F, Clauw DJ, Fitzcharles MA, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol. 2011;38(6):1113–1122.
5Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. Arthritis Rheum. 2004;50(3):944–952.
6Buskila D, Atzeni F, Sarzi-Puttini P. Etiology of fibromyalgia: the possible role of infection and vaccination. Autoimmun Rev. 2008;8(1):41–43.
7Phillips K, Clauw DJ. Central pain mechanisms in the rheumatic diseases: future directions. Arthritis Rheum. 2013;65(2):291–302.
8Häuser W, Bernardy K, Arnold B, Offenbächer M, Schiltenwolf M. Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. Arthritis Rheum. 2009;61(2):216–224.
9Bernardy K, Füber N, Köllner V, Häuser W. Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome: a systematic review and meta-analysis of randomized controlled trials. J Rheumatol. 2010;37(10):1991–2005.
10Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics. 2000;41(2):104–113.
11Arnold LM. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med. 2007;8(suppl 2):S63–S74.
12Schmidt-Wilcke T, Clauw D.J. Fibromyalgia: from pathophysiology to therapy. Nat. Rev. Rheumatol. 2011;7: 518–527.